Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label multicenter study of CM355 in relapsed or refractory B-cell non-Hodgkin lymphoma
CTR20212578Phase 2Completed
- Sponsor
- TNJC Biotech
- Start
- Jan 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CM355 in mature B-cell lymphoma, sponsored by TNJC Biotech. Started Jan 2022; status: completed.
02
Drugs
CM355
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on CTR20212578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212578.